ZOVIRAX VIRAL RESISTANCE POTENTIAL IS PRIMARY ISSUE TO BE ADDRESSED BY FDA IN REVIEW OF B-W OTC SWITCH APPLICATION, FDA ADVISORY COMMITTEES TELL AGENCY
Executive Summary
The potential emergence of viral resistance to Zovirax is the primary issue FDA should address in its review of Burroughs Wellcome's OTC switch application for acyclovir, FDA's Nonprescription Drugs & Antiviral Drugs Advisory Committees agreed May 19.